A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma
What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2 every 3 weeks)in squamous cell carcinoma of the head and neck.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Last Updated:
- Study HIC#: